doi:10.1016/j.ctarc.2021.100355engAl-Wasaby, S.Guerrero-Ochoa, P.Ibáñez-Pérez, R.Soler, R.Conde, B.Martínez-Lostao, L.Anel, A.In vivo potential of recombinant granulysin against human melanomaART-2021-1243829-kDa granulysin is a protein expressed into the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. It has been shown to exert cytolysis on microbes and tumors. We showed previously that 9-kDa granulysin exerted cell death by apoptosis in vitro on hematological tumor cell lines and also on cells from B-cell chronic lymphocytic leukemia (B-CLL) patients. In addition, we have shown the anti-tumor efficiency of granulysin as a single agent in two in vivo models of human tumor development in athymic mice, the MDA-MB-231 mammary adenocarcinoma and the NCI-H929 multiple myeloma, without signs of overt secondary effects by itself. In this work, we have tested recombinant 9-kDa granulysin in an in vivo and especially aggressive model of melanoma development, xenografted UACC62 cells in athymic mice. Recombinant granulysin was administered once UACC62-derived tumors were detectable and it substantially retarded the in vivo development of this aggressive tumor. We could also detect apoptosis induction and increased NK cell infiltration inside granulysin-treated tumor tissues. These observations are especially interesting given the possibility of treating melanoma by intra-tumor injection.2021http://zaguan.unizar.es/record/10221110.1016/j.ctarc.2021.100355http://zaguan.unizar.es/record/102211oai:zaguan.unizar.es:102211info:eu-repo/grantAgreement/ES/DGA/B31-17Rinfo:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-RCancer Treatment and Research Communications 27 (2021), 100355 [7 pp.]by-nc-ndhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccess